Kang et al. (51) found that CD137−/− mice and agonistic anti-CD137 antibody-treated mice had better anti-tumor immune responses because of an increased differentiation of myeloid cells to CD103+ DCs and type 1 macrophages. This evidence concerns the gene TNFRSF9 and neoplasm.